Galderma Group AG (XSWX:GALD) Revenue: CHF4,217 Mil (TTM As of Dec. 2025)


XSWX:GALD Galderma Group AG XSWX:GALD
15 GF Score
Price CHF178.35
! 4 Warning Signs
View Full Analysis

What is Galderma Group AG Revenue?

Galderma Group AG XSWX:GALD -0.67% 15 Revenue is CHF4,217 Mil as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review.

Galderma Group AG's revenue for the six months ended in Dec. 2025 was CHF2,211 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was CHF4,217 Mil. Galderma Group AG's Revenue per Share for the six months ended in Dec. 2025 was CHF9.36. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.80.

During the past 12 months, the average Revenue per Share Growth Rate of Galderma Group AG was 5.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 5.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 5 years, Galderma Group AG's highest 3-Year average Revenue per Share Growth Rate was 7.60% per year. The lowest was 5.50% per year. And the median was 6.55% per year.

Galderma Group AG  (XSWX:GALD) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Galderma Group AG Revenue Related Terms

Galderma Group AG Revenue Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Revenue Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
3,172.85 3,562.35 3,560.38 3,958.70 4,176.55

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial 1,817.81 1,980.66 1,982.92 2,005.35 2,211.40

XSWX:GALD vs ZTS, UTHR, VTRS: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galderma Group AG Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's Revenue distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's Revenue falls into.


XSWX:GALD
15GF Score
Galderma Group AG XSWX:GALD
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF4,217 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of CHF4,217 Mil mean?
Galderma Group AG (XSWX:GALD) has a Revenue of CHF4,217 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Galderma Group AG and its competitors.
Is Galderma Group AG's Revenue too high?
Galderma Group AG's current Revenue is CHF4,217 Mil. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Revenue compare to ZTS and UTHR?
Galderma Group AG's Revenue of CHF4,217 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Galderma Group AG and its competitors. Galderma Group AG's current Revenue is CHF4,217 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Revenue of CHF4,217 Mil. The current Revenue is CHF4,217 Mil. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Revenue is CHF4,217 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score

Get the complete analysis for XSWX:GALD

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF178.35
Price